What Is the First-Line Treatment of Hirsutism?
Clinical Scenario
Hirsutism — patient-important excess terminal hair growth — is addressed through a structured first-line pharmacological strategy before escalation or combination therapy is considered.
Treatment Goal
The primary clinical target is a measurable reduction in the Ferriman–Gallwey hirsutism score. Because of the length of the hair growth cycle, response to hormonal therapy becomes detectable at approximately 6 months, with maximum effect at around 9 months.
Approach (partial overview)
Initial pharmacological management involves a combined oral estrogen–progestin contraceptive given as monotherapy — the full protocol specifies the selection criteria, the recommended duration of trial before any regimen change, and the conditions under which direct hair removal methods may be added.
The complete sequencing, decision points, and clinical rules are available in the structured protocol below.
References
DOI: 10.1210/jc.2018-00241
- For most women with patient-important hirsutism despite cosmetic measures, we suggest starting with pharmacological therapy (2 |OOO).
- For the majority of women with hirsutism who are not seeking fertility, we suggest OCs as initial therapy for treating patient-important hirsutism. (2 |OO)
- For all pharmacologic therapies for hirsutism, we suggest a trial of at least 6 months before making changes in dose, switching to a new medication, or adding medication. (2 |OOO)
- For women who then desire additional cosmetic benefit, we suggest adding direct hair removal methods.
- Due to the long hair growth cycle, it takes ≥6 months to detect the effects of hormonal therapy and ≥9 months for these effects to become maximal.
View source ↗